<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Acquisition</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Laborie acquires Jada from Organon in $465M deal</title>
      <description>
        <![CDATA[Laborie Medical Technologies Corp. secured a new gem for its maternal health with the acquisition of the Jada system from Organon & Co. The terms of the deal, first announced in November, included payment of $440 million at closing, with an additional $25 million tied to 2026 revenue targets.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728284</guid>
      <pubDate>Fri, 30 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728284-laborie-acquires-jada-from-organon-in-465m-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/04-01-Organon-Alydia-Jada.webp?t=1769799622" type="image/png" medium="image" fileSize="496662">
        <media:title type="plain">Jada device image</media:title>
        <media:description type="plain">Jada system for treatment of postpartum hemorrhage. Credit: Alydia Health</media:description>
      </media:content>
    </item>
    <item>
      <title>Hologic to go private in $18.3B deal</title>
      <description>
        <![CDATA[In the largest med-tech M&A deal in nearly three years, Hologic Inc. agreed to be acquired by funds led by Blackstone and TPG in a transaction valued at $18.3 billion. After five months of rumored negotiations, the outlined deal provides Hologic shareholders with $76 per share in cash plus up to $3 per share in contingent value rights (CVR) to be paid on achievement of revenue goals for the breast health business over the next two years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725145</guid>
      <pubDate>Tue, 21 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725145-hologic-to-go-private-in-183b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Glass-globe-with-documents-and-pen.webp?t=1759956850" type="image/jpeg" medium="image" fileSize="456537">
        <media:title type="plain">Glass globe with documents and pen</media:title>
      </media:content>
    </item>
    <item>
      <title>US FTC moves to thwart Edwards’ acquisition of Jenavalve</title>
      <description>
        <![CDATA[The U.S. Federal Trade Commission (FTC) reported Aug. 6 that it will try to block Edwards Lifesciences Corp.’s proposed acquisition of Jenavalve because Edwards’ acquisition of both Jenavalve Technology Inc. and JC Medical would eliminate competition in the TAVR space for aortic regurgitation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722673</guid>
      <pubDate>Thu, 07 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722673-us-ftc-moves-to-thwart-edwards-acquisition-of-jenavalve</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Gavel-and-FTC-logo.webp?t=1684261926" type="image/jpeg" medium="image" fileSize="189378">
        <media:title type="plain">Gavel and FTC logo</media:title>
      </media:content>
    </item>
    <item>
      <title>Bio-Techne takes a hit on Exodx sale to Mdxhealth</title>
      <description>
        <![CDATA[Bio-Techne Corp. plans to sell its Exosome Diagnostics Inc. business to Mdxhealth SA for $15 million plus royalty payments, a steep cut from the $250 million the company paid to acquire Exodx in 2018. Mdxhealth estimates the unit will generate $20 million in revenue in 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722664</guid>
      <pubDate>Wed, 06 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722664-bio-techne-takes-a-hit-on-exodx-sale-to-mdxhealth</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Red-arrow-pointing-downward-on-a-stock-market-ticker.webp?t=1746653867" type="image/jpeg" medium="image" fileSize="239034">
        <media:title type="plain">Red arrow pointing downward on a stock market ticker</media:title>
      </media:content>
    </item>
    <item>
      <title>Bright move: Alcon offers $1.5B for Staar Surgical</title>
      <description>
        <![CDATA[Alcon AG agreed to acquire Staar Surgical Co. in a $1.5 billion cash transaction that would add Staar’s Evo implantable Collamer lenses (ICL) to treat myopia to the vision giant’s portfolio. Alcon will pay $28 per share, a 59% premium on Staar’s 90-day volume-weighted average price and a 51% premium on the Aug. 4 closing price of its shares (Nasdaq: STAA). ]]>
      </description>
      <guid>http://www.bioworld.com/articles/722654</guid>
      <pubDate>Tue, 05 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722654-bright-move-alcon-offers-15b-for-staar-surgical</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Acquisition-puzzle.webp?t=1682968589" type="image/jpeg" medium="image" fileSize="193595">
        <media:title type="plain">Acquisition puzzle</media:title>
      </media:content>
    </item>
    <item>
      <title>Illumina buying Somalogic for up to $425M to boost multiomics assets</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[In a bid to boost its multiomics holdings, Illumina Inc. reported an agreement to buy proteomics technology company Somalogic Inc. from Standard Biotools Inc. for $350 million in cash, plus up to $75 million in near-term performance-based milestones and performance-based royalties.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721209</guid>
      <pubDate>Mon, 23 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721209-illumina-buying-somalogic-for-up-to-425m-to-boost-multiomics-assets</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Research-deal-collaboration-handshake.webp?t=1742309543" type="image/jpeg" medium="image" fileSize="227377">
        <media:title type="plain">Scientists shaking hands in the lab</media:title>
      </media:content>
    </item>
    <item>
      <title>23andme founder-led group outbids Regeneron for company</title>
      <description>
        <![CDATA[The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against Regeneron Pharmaceuticals Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721112</guid>
      <pubDate>Mon, 16 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721112-23andme-founder-led-group-outbids-regeneron-for-company</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Telomeres-and-DNA-illustration.webp?t=1745438832" type="image/jpeg" medium="image" fileSize="171418">
        <media:title type="plain">Telomeres and DNA illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Alteogen merges two subsidiaries, forming Alteogen Biologics</title>
      <description>
        <![CDATA[Alteogen Inc. completed a merger between two subsidiaries – Altos Biologics Inc. and Alteogen Healthcare Inc. – branding the new entity as Alteogen Biologics Inc. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/720695</guid>
      <pubDate>Tue, 27 May 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720695-alteogen-merges-two-subsidiaries-forming-alteogen-biologics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Alteogen-headquarters-11-11.webp?t=1748032929" type="image/jpeg" medium="image" fileSize="233436">
        <media:title type="plain">Alteogen headquarters in Daejeon, South Korea</media:title>
        <media:description type="plain">Alteogen headquarters in Daejeon, South Korea. Credit: Alteogen Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Alteogen merges two subsidiaries, forming Alteogen Biologics</title>
      <description>
        <![CDATA[Alteogen Inc. completed a merger between two subsidiaries – Altos Biologics Inc. and Alteogen Healthcare Inc. – branding the new entity as Alteogen Biologics Inc. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/720469</guid>
      <pubDate>Fri, 23 May 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720469-alteogen-merges-two-subsidiaries-forming-alteogen-biologics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Alteogen-headquarters-11-11.webp?t=1748032929" type="image/jpeg" medium="image" fileSize="233436">
        <media:title type="plain">Alteogen headquarters in Daejeon, South Korea</media:title>
        <media:description type="plain">Alteogen headquarters in Daejeon, South Korea. Credit: Alteogen Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Alcon to acquire Lensar for up to $430M</title>
      <description>
        <![CDATA[Alcon AG plans to acquire Lensar Inc. for up to $430 million in a transaction expected to close in the latter half of the year. The acquisition will add Lensar’s Ally robotic cataract laser treatment system, Streamline software technology and Lensar legacy laser system to Alcon’s cataract surgery portfolio and expand global access to Lensar’s femtosecond laser technology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718199</guid>
      <pubDate>Mon, 24 Mar 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718199-alcon-to-acquire-lensar-for-up-to-430m</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-between-hands.webp?t=1740610521" type="image/jpeg" medium="image" fileSize="123345">
        <media:title type="plain">Dollar sign between hands</media:title>
      </media:content>
    </item>
    <item>
      <title>GC Biopharma to buy Abo Holdings for ₩138B, grow US plasma biz</title>
      <description>
        <![CDATA[GC Biopharma Corp. will buy plasma collector Abo Holdings Inc. in a ₩138 billion (US$96.28 million) cash acquisition as the vaccine and plasma-derived medicinal products developer works to accelerate entry of Alyglo (IVIG-SN 10%) in the U.S., where it was approved last year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/715509</guid>
      <pubDate>Tue, 17 Dec 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715509-gc-biopharma-to-buy-abo-holdings-for-138b-grow-us-plasma-biz</link>
    </item>
    <item>
      <title>GC Biopharma to buy Abo Holdings for ₩138B, grow US plasma biz</title>
      <description>
        <![CDATA[GC Biopharma Corp. will buy plasma collector Abo Holdings Inc. in a ₩138 billion (US$96.28 million) cash acquisition as the vaccine and plasma-derived medicinal products developer works to accelerate entry of Alyglo (IVIG-SN 10%) in the U.S., where it was approved last year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/715343</guid>
      <pubDate>Fri, 13 Dec 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715343-gc-biopharma-to-buy-abo-holdings-for-138b-grow-us-plasma-biz</link>
    </item>
    <item>
      <title>August gathers $100M in med-tech M&amp;As amid falling deal values</title>
      <description>
        <![CDATA[Med-tech deal values dipped to $1.73 million in August, the lowest monthly total seen in 2024 and a steep drop from July’s $200.88 million.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712234</guid>
      <pubDate>Mon, 16 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712234-august-gathers-100m-in-med-tech-m-and-as-amid-falling-deal-values</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/cash-dollar-bills-raining.webp?t=1623360647" type="image/png" medium="image" fileSize="1054358">
        <media:title type="plain">Raining 100 dollar bills</media:title>
      </media:content>
    </item>
    <item>
      <title>SK Bioscience to acquire Klocke’s CDMO in cross-holding M&amp;A </title>
      <description>
        <![CDATA[South Korea’s SK Bioscience Co. Ltd. has entered a cross-shareholding acquisition deal with Germany’s Klocke Pharma-Service GmbH to acquire its contract development and manufacturing organization (CDMO), IDT Biologika Corp.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710243</guid>
      <pubDate>Tue, 02 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710243-sk-bioscience-to-acquire-klockes-cdmo-in-cross-holding-m-and-a</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2024/Jaeyong-Ahn-CEO-and-president-SK-Bioscience-6-27.webp?t=1719519647" type="image/jpeg" medium="image" fileSize="211879">
        <media:title type="plain">Jaeyong Ahn, CEO and president, SK Bioscience </media:title>
        <media:description type="plain">Jaeyong Ahn, CEO and president of SK Bioscience, at a press conference in Seoul, South Korea on June 27. Credit: SK Bioscience</media:description>
      </media:content>
    </item>
    <item>
      <title>SK Bioscience to acquire Klocke’s CDMO in cross-holding M&amp;A </title>
      <description>
        <![CDATA[South Korea’s SK Bioscience Co. Ltd. has entered a cross-shareholding acquisition deal with Germany’s Klocke Pharma-Service GmbH to acquire its contract development and manufacturing organization (CDMO), IDT Biologika Corp.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710082</guid>
      <pubDate>Thu, 27 Jun 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710082-sk-bioscience-to-acquire-klockes-cdmo-in-cross-holding-m-and-a</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2024/Jaeyong-Ahn-CEO-and-president-SK-Bioscience-6-27.webp?t=1719519647" type="image/jpeg" medium="image" fileSize="211879">
        <media:title type="plain">Jaeyong Ahn, CEO and president, SK Bioscience </media:title>
        <media:description type="plain">Jaeyong Ahn, CEO and president of SK Bioscience, at a press conference in Seoul, South Korea on June 27. Credit: SK Bioscience</media:description>
      </media:content>
    </item>
    <item>
      <title>Quest and Pathai sign multipart collaboration</title>
      <description>
        <![CDATA[Quest Diagnostics Inc. and Pathai Inc. established a forward-looking deal with multiple components and room for growth. The collaboration includes Quest’s acquisition of Pathai Diagnostics – the division that provides anatomic and digital pathology laboratory services – and licensing of Pathai’s Aisight digital pathology image management system. The companies also said they may work together on development of Pathai’s algorithm products and that Quest will be a preferred provider for Pathai’s biopharmaceutical clinical laboratory services.]]>
      </description>
      <guid>http://www.bioworld.com/articles/707938</guid>
      <pubDate>Thu, 02 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/707938-quest-and-pathai-sign-multipart-collaboration</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Digital-MA-screen.webp?t=1710363128" type="image/jpeg" medium="image" fileSize="184805">
        <media:title type="plain">Hand pointing at digital M&amp;A screen</media:title>
      </media:content>
    </item>
    <item>
      <title>USTR’s Tai sees state champions as anticompetitive policy instruments</title>
      <description>
        <![CDATA[Life science companies and the Office of the U.S. Trade Representative have not always seen eye to eye on issues such as compulsory licensing, but industry might be supportive of a remark by U.S. Trade Representative Katherine Tai about companies that are provided with anticompetitive breathing by their host governments with noticeable anticompetitive effect. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/707129</guid>
      <pubDate>Mon, 08 Apr 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/707129-ustrs-tai-sees-state-champions-as-anticompetitive-policy-instruments</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Gavel-and-FTC-logo.webp?t=1684261926" type="image/jpeg" medium="image" fileSize="189378">
        <media:title type="plain">Gavel and FTC logo</media:title>
      </media:content>
    </item>
    <item>
      <title>Johnson Matthey to sell medical device business for $700M</title>
      <description>
        <![CDATA[Johnson Matthey plc agreed to sell its medical device components business to Montagu Private Equity for £550 million ($700 million) on a cash-free, debt-free basis. For Montagu, the deal is part of its expanding health care portfolio. Earlier in 2024 the private equity firm, which is the primary shareholder in RTI Surgical Inc., acquired Cook Biotech Inc. from Cook Medical Inc. and merged the two companies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706465</guid>
      <pubDate>Fri, 22 Mar 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/706465-johnson-matthey-to-sell-medical-device-business-for-700m</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Coins-and-paperwork.webp?t=1683744376" type="image/jpeg" medium="image" fileSize="206338">
        <media:title type="plain">Coins and financial paperwork</media:title>
      </media:content>
    </item>
    <item>
      <title>February sees rise in med-tech deal volume while value dips from last year</title>
      <description>
        <![CDATA[Med-tech deal value in February jumped to $255.61 million, an increase of 137.23% from the $107.75 million in deals from January, yet below the 2023 monthly average of $886.13 million. On the M&A front, med-tech transactions hit their lowest point since May 2019, totaling only $16 million.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706437</guid>
      <pubDate>Tue, 19 Mar 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/706437-february-sees-rise-in-med-tech-deal-volume-while-value-dips-from-last-year</link>
    </item>
    <item>
      <title>Haemonetics to acquire Attune Medical for cool $160M</title>
      <description>
        <![CDATA[Haemonetics Corp. appears ready to make a bit of a retro investment, as it entered into a definitive agreement to acquire Advanced Cooling Therapy Inc. (dba Attune Medical) for $160 million at closing plus undisclosed additional contingent payments. Attune manufactures the U.S. FDA-cleared Ensoetm device, which cools the esophagus during radiofrequency cardiac ablation procedures, a treatment for atrial fibrillation whose days appeared numbered.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705985</guid>
      <pubDate>Wed, 06 Mar 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705985-haemonetics-to-acquire-attune-medical-for-cool-160m</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/EnsoETM_inserted_6mar24.webp?t=1709761492" type="image/jpeg" medium="image" fileSize="127553">
        <media:title type="plain">EnsoETM</media:title>
        <media:description type="plain">Attune Medical’s Ensoetm protects the esophagus during radiofrequency ablation procedures. Credit: Attune Medical</media:description>
      </media:content>
    </item>
    <item>
      <title>Eilean Therapeutics acquires PTPN2 inhibitors</title>
      <description>
        <![CDATA[Eilean Therapeutics LLC has announced the acquisition of Ness Therapeutics Inc. in an all-equity transaction, including Ness’ best-in-class tyrosine-protein phosphatase non-receptor type 2 (PTPN2) inhibitors with application in immuno-oncology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706274</guid>
      <pubDate>Tue, 05 Mar 2024 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/706274-eilean-therapeutics-acquires-ptpn2-inhibitors</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cells-receptors-inhibitors.webp?t=1667926694" type="image/png" medium="image" fileSize="1347625">
        <media:title type="plain">Concept art for cells receptors, inhibitors</media:title>
      </media:content>
    </item>
    <item>
      <title>CG Bio claims majority stake in Inosys Korea</title>
      <description>
        <![CDATA[South Korea’s Cell & Growth Factor Biotechnology Co. Ltd. (CG Bio) became the largest shareholder of Busan-based Inosys Korea after claiming a 34.7% stake in the embattled orthopedic implant med-tech firm.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705863</guid>
      <pubDate>Wed, 28 Feb 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705863-cg-bio-claims-majority-stake-in-inosys-korea</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/AI-binary-science-medical-research.webp?t=1698157716" type="image/jpeg" medium="image" fileSize="555712">
        <media:title type="plain">Science and medicine icons with head made of computer code</media:title>
      </media:content>
    </item>
    <item>
      <title>Bruker acquires molecular diagnostics provider Elitech for €870M</title>
      <description>
        <![CDATA[Continuing its aggressive buying spree, Bruker Corp. entered into a definitive share purchase agreement with Tecfin S.à r.l. to acquire molecular diagnostics (MDx) company Elitechgroup SAS for €870 million (US$943.5 million), excluding the Elitech clinical chemistry business. The deal is expected to close in the second quarter of 2024 and will be funded with a mix of cash on hand and debt financing.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705861</guid>
      <pubDate>Wed, 28 Feb 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705861-bruker-acquires-molecular-diagnostics-provider-elitech-for-870m</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Stock-merger-illustration.webp?t=1620238968" type="image/png" medium="image" fileSize="458135">
        <media:title type="plain">Stock merger illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Zimmer Biomet wins new FDA clearance of Rosa robotic shoulder system</title>
      <description>
        <![CDATA[Zimmer Biomet Holdings Inc.’s Rosa robotics surgical assistant snapped up its fourth application with the U.S. FDA’s 510(k) clearance for use in shoulder replacement surgery. Over the past five years, the system has built a portfolio that includes partial and total knee replacement and total hip replacement.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705458</guid>
      <pubDate>Fri, 23 Feb 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705458-zimmer-biomet-wins-new-fda-clearance-of-rosa-robotic-shoulder-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Zimmer-Bio-Rosa-shoulder-23feb24.webp?t=1708725612" type="image/jpeg" medium="image" fileSize="57467">
        <media:title type="plain">Zimmer Biomet Rosa shoulder</media:title>
        <media:description type="plain">Zimmer Biomet’s Rosa Shoulder surgical robot granted FDA clearance. Credit: Courtesy Zimmer Biomet</media:description>
      </media:content>
    </item>
    <item>
      <title>Med-tech deals soar to record high in 2023, digital health still dominates</title>
      <description>
        <![CDATA[Despite a slowdown in the fourth quarter (Q4), med-tech deals concluded the year with the highest deal-value total in BioWorld MedTech’s records. In 2023, a total of $10.63 billion was raised from deals, a 33% increase over the $7.99 billion deal total in 2022. Meanwhile, annual M&A value dropped 58%, from $153.09 billion in 2022 to $64.8 billion in 2023.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705276</guid>
      <pubDate>Fri, 16 Feb 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705276-med-tech-deals-soar-to-record-high-in-2023-digital-health-still-dominates</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Calculator-fees-US-dollars-financial.webp?t=1619815841" type="image/png" medium="image" fileSize="1733186">
        <media:title type="plain">Calculator, 100 dollar bills</media:title>
      </media:content>
    </item>
    <item>
      <title>Adagio speeds up financing rhythm with $42M SPAC deal</title>
      <description>
        <![CDATA[The slow pace of financing in med-tech appears to have stimulated cardiac arrhythmia technology developer Adagio Medical Inc. to turn to a special purpose acquisition company (SPAC) in a type of deal that has all but vanished in the last year. The company signed an agreement with Arya Sciences Acquisition Corp. IV to combine in a reverse merger deal that will result in Adagio’s listing on Nasdaq under “ADGM.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/705272</guid>
      <pubDate>Fri, 16 Feb 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705272-adagio-speeds-up-financing-rhythm-with-42m-spac-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/adagio_16feb24.webp?t=1708124844" type="image/jpeg" medium="image" fileSize="73709">
        <media:title type="plain">Adagio</media:title>
        <media:description type="plain">Adagio’s continuous lesion ablation system (ICLAS) ultra-low temperature cryoablation system. Credit: Adagio</media:description>
      </media:content>
    </item>
    <item>
      <title>January launches med-tech firms with $100M in deals, $1.43B in M&amp;As</title>
      <description>
        <![CDATA[The new year kicked off with med-tech deal value in January totaling $107.75 million. By the numbers, January’s 183 deals surpassed the 2023 monthly average of approximately 142 deals per month.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705088</guid>
      <pubDate>Fri, 09 Feb 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705088-january-launches-med-tech-firms-with-100m-in-deals-143b-in-m-and-as</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/DNA-with-bar-chart.webp?t=1707510184" type="image/jpeg" medium="image" fileSize="103185">
        <media:title type="plain">DNA with bar chart</media:title>
      </media:content>
    </item>
    <item>
      <title>Med-tech financings maintain momentum with $1B raised in January</title>
      <description>
        <![CDATA[In the first month of 2024, med-tech financings passed the $1 billion mark once more, raising a total of $1.06 billion through 46 transactions recorded by <em>BioWorld</em>. It was the fourth consecutive month where med-tech financings exceeded the $1 billion threshold, just slightly down from the $1.07 billion raised in December.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705047</guid>
      <pubDate>Mon, 05 Feb 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705047-med-tech-financings-maintain-momentum-with-1b-raised-in-january</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/med-tech-financings-jan24.webp?t=1707168923" type="image/jpeg" medium="image" fileSize="35774">
        <media:title type="plain">med-tech financings</media:title>
      </media:content>
    </item>
    <item>
      <title>Synchron acquires equity stake in Acquandas</title>
      <description>
        <![CDATA[Synchron Inc. has acquired an equity stake in German manufacturer Acquandas GmbH in a move that will strengthen the company’s innovation and supply chain for its brain-computer interface system, Synchron founder and CEO Tom Oxley said.]]>
      </description>
      <guid>http://www.bioworld.com/articles/704959</guid>
      <pubDate>Fri, 02 Feb 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/704959-synchron-acquires-equity-stake-in-acquandas</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Synchron-Stentrode-brain-implant-02feb24.webp?t=1706914108" type="image/jpeg" medium="image" fileSize="52908">
        <media:title type="plain">Synchron Stentrode brain implant</media:title>
        <media:description type="plain"> Synchron Inc’s Stentrode brain computer interface implant. Credit: Synchron</media:description>
      </media:content>
    </item>
    <item>
      <title>Trinity transforming into CGM player with $12.5M acquisition, Bayer partnership</title>
      <description>
        <![CDATA[Trinity Biotech plc. paid $12.5 million to acquire Waveform Technologies Inc.’s biosensor and continuous glucose monitoring (CGM) assets. It also formed a partnership with Bayer AG to launch a CGM biosensor in China and India. These moves are part of Trinity’s transformation strategy to become a leading player in wearable biosensor technology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/704946</guid>
      <pubDate>Thu, 01 Feb 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/704946-trinity-transforming-into-cgm-player-with-125m-acquisition-bayer-partnership</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/WaveForm-cgm-1feb24.webp?t=1706826836" type="image/jpeg" medium="image" fileSize="72761">
        <media:title type="plain">WaveForm cgm</media:title>
        <media:description type="plain">Waveform Technologies Inc.’s biosensor and continuous glucose monitoring. Credit: courtesy Waveform</media:description>
      </media:content>
    </item>
  </channel>
</rss>
